ANL_46_6_927.pdf 115 KB
Fig_table.pdf 204 KB
Makihara, Seiichiro Department of Otolaryngology-Head & Neck Surgery, Kagawa Rosai Hospital
Kariya, Shin Department of Otolaryngology-Head & Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences ORCID Kaken ID publons researchmap
Noujima-Harada, Mai Department of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences,
Ohara, Nobuya Department of Pathology, Kagawa Rosai Hospital
Naito, Tomoyuki Department of Otolaryngology-Head & Neck Surgery, Kagawa Rosai Hospital
Matsumoto, Junya Department of Otolaryngology-Head & Neck Surgery, Kagawa Rosai Hospital
Noda, Yohei Department of Otolaryngology-Head & Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Okano, Mitsuhiro Department of Otolaryngology, International University of Health and Welfare School of Medicine
Yoshino, Tadashi Department of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Kaken ID publons researchmap
As has been well recognized, methotrexate (MTX) leads to a state of immunosuppression and can provide a basis for the development of lymphoproliferative disorders (LPDs). MTX-associated LPDs can affect nodal sites as well as extranodal sites, though the manifestation of an LPD in the form of multiple pulmonary nodules is rare. Here, we report two cases of MTX-associated LPD with multiple bilateral pulmonary nodules, which was a finding suggestive of lung cancer, and bilateral cervical lymphadenopathy. After withdrawal of MTX, the multiple bilateral pulmonary nodules and bilateral cervical lymphadenopathy disappeared without chemotherapy in both cases. From these results, patients with pulmonary nodules and cervical lymphadenopathy should be examined for head and neck malignant tumors. Also, physicians should carefully check the administration of MTX. In patients with an MTX-associated LPD, we need to make an early diagnosis and consider discontinuing the administration of MTX as soon as possible.
This fulltext will be available in Aug 2020
Auris Nasus Larynx
© 2019 Elsevier B.V. All rights reserved.
|Web of Science KeyUT|
Seiichiro Makihara, Shin Kariya, Mai Noujima-Harada, Nobuya Ohara, Tomoyuki Naito, Junya Matsumoto, Yohei Noda, Mitsuhiro Okano, Tadashi Yoshino, Kazunori Nishizaki, Methotrexate-associated lymphoproliferative disorder with multiple pulmonary nodules and bilateral cervical lymphadenopathy, Auris Nasus Larynx, Volume 46, Issue 6, 2019, Pages 927-933, ISSN 0385-8146, https://doi.org/10.1016/j.anl.2019.01.010.